1. CDK4/6 Inhibitors in Practice

2. Efficacy of CDK4/6 Inhibitors: Two Different Settings

3. Are All the CDK4/6 Inhibitors Created Equal?

4. CDK4/6 Inhibitors: Consistency of Response

5. Clinical Endpoints of Interest in MBC Trials

6. PALOMA-3: Global QoL, Functioning, and Symptoms

7. FALCON Trial: Subgroup Analysis

8. MONARCH-3: PFS Bone-Only Disease

9. Future Questions

10. CDK4/6 Inhibitors and Clinical Profiles

11. Unanswered Questions

12. Clinical Considerations

13. Future Studies

14. Concluding Remarks

15. CDK4/6 Inhibitors in Premenopausal Patients

16. PALOMA-3: Palbociclib Plus Fulvestrant vs Fulvestrant

17. CDK4/6 Inhibitors in Premenopausal Women Clinical Considerations

18. MONARCH-2: Abemaciclib Plus Fulvestrant vs Fulvestrant

19. MONALEESA-7: Ribociclib Plus Goserelin and Tamoxifen/AI vs Goserelin and Tamoxifen/AI

20. Concluding Remarks

21. Impact of CDK4/6 Inhibitors on the Treatment Sequence

22. CDK4/6 Inhibitors: Providing Therapeutic Benefit

23. CDK4/6 Inhibitors: Unanswered Questions Remain Regarding Sequencing

24. PALOMA-3: Postprogression Therapies

25. Future Studies Are Needed

26. Concluding Remarks

27. Selecting the Right Endocrine Partner for CDK 4/6 Inhibitors

28. The Cell Cycle and CDKs

29. CDK4/6 Inhibitors: Differences in ET Strategy in Clinical Trials

32. PARSIFAL Trial

33. Concluding Remarks

34. Resistance to CDK4/6 Inhibitors

35. Mechanisms of Resistance to CDK4/6 Inhibitors

36. Primary Resistance

37. Secondary Resistance: CDK2 Activation

38. Secondary Resistance: RB1 Mutation

39. Secondary Resistance: Amplification of CDK6

40. Implications to Clinical Practice

41. Resistance to CDK4/6 Inhibitors: Clinical Considerations

42. Concluding Remarks

43. Abbreviations

44. Abbreviations (cont)

45. Abbreviations (cont)